Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) (CaBaMet)

This study has suspended participant recruitment.
(After a recruitment of more than 2 years, only 8 patients have been registered.)
Sponsor:
Collaborators:
ClinAssess GmbH
Sanofi
Information provided by (Responsible Party):
AIO-Studien-gGmbH
ClinicalTrials.gov Identifier:
NCT02166658
First received: June 16, 2014
Last updated: March 6, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)